Investors were shocked to learn that Biogen now plans to pursue regulatory approval for the experimental Alzheimer’s disease drug they previously pulled the plug on. But Heard on the Street's Charley Grant explains why the optimism may be premature. Photo: Brian Snyder/Reutersfrom WSJ.com Video - Most Viewed WSJ Videos https://ift.tt/2WeYFIB

No comments:
Post a Comment